Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 0.57 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.51 |
| ▸ | NQO1 | P15559 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14329527 | 1.00 | PTGS2 (0.57) | PTGS2CA12CA1CA9KCNA3 | |
| SCHEMBL14329525 | 0.89 | PTGS2 (0.55) | PTGS2CA12CA1CA9KCNA3 | |
| SCHEMBL14329522 | 0.87 | PTGS2 (0.55) | PTGS2CA12CA1CA9KCNA3 | |
| SCHEMBL15843118 | 0.84 | PTGS2 (0.59) | PTGS2CA12CA1CA9KCNA3 | |
| SCHEMBL14802519 | 0.84 | PTGS2 (0.51) | PTGS2CA12CA1CA9KCNA3 | |
| SCHEMBL14329531 | 0.82 | PTGS2 (0.56) | PTGS2CA12CA1CA9KCNA3 | |
| SCHEMBL15842782 | 0.78 | CYP2A6 (0.67) | CA12CA1CA9KCNA3NQO1 | |
| SCHEMBL15864643 | 0.78 | NQO1 (0.56) | PTGS2CA12CA1CA9KCNA3 | |
| SCHEMBL12216153 | 0.78 | ALDH1A1 (0.54) | PTGS2CA12CA1CA9KCNA3 | |
| SCHEMBL14802542 | 0.78 | CA12 (0.61) | PTGS2CA12CA1CA9KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130079394-A1 | Indirect modeling of new repellent molecules active against insects, acarids, and other arthropods | CNRS (CENTRE NATIONAL RECHERCHE SCIENTIFIQUE) (FR) | 2013-03-28 | — | — | US | disclosed |
| US-20130079394-A1 | Indirect modeling of new repellent molecules active against insects, acarids, and other arthropods | CNRS (CENTRE NATIONAL RECHERCHE SCIENTIFIQUE) (FR) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079394-A1 | Indirect modeling of new repellent molecules active against insects, acarids, and other arthropods | NISCH, ACAT2, CIAPIN1 | PTGS2 4622/4885CA12 3214/4885CA1 2751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.